Nivolumab-associated IgA Nephropathy in a Child With Malignant Melanoma

J Pediatr Hematol Oncol. 2024 Oct 1;46(7):e534-e536. doi: 10.1097/MPH.0000000000002931. Epub 2024 Jul 25.

Abstract

Immune checkpoint inhibitors are humanized antibodies that inhibit downregulatory receptors on T cells, enhancing the antitumor activity of these cells. However, they have been associated with a wide range of systemic immune-related adverse events, including renal toxicities, among others. Most renal immune-related adverse events are acute interstitial nephritis causing acute kidney injury. Recently, immune checkpoint inhibitors-associated glomerular diseases, including IgA nephropathy, have been reported in adults. Most of the adult cases with glomerular involvement had also concomitant acute interstitial nephritis and acute kidney injury. We present the first pediatric case of IgA nephropathy without acute kidney injury during nivolumab treatment.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects
  • Child
  • Female
  • Glomerulonephritis, IGA* / chemically induced
  • Glomerulonephritis, IGA* / drug therapy
  • Glomerulonephritis, IGA* / pathology
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Male
  • Melanoma* / drug therapy
  • Nivolumab* / adverse effects

Substances

  • Nivolumab
  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents, Immunological